MDXG News and Press, MiMedx Group Inc From 11/03/20

MiMedx Group (MDXG) announces that the largest U.S. commercial payor will cover its EpiFix tissue product for the treatment of diabetic foot ulcers effective December 1.Beleaguered longs are hoping the news lifts the stock considering its 20% drop this year. For further details se...

Only Amniotic Product Covered Under Updated Commercial Policy MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) --  MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics com...

MARIETTA, Ga., Oct. 30, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that The Nasdaq Stock Market LLC has approved MiMedx&#...

MARIETTA, Ga., Oct. 29, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the third qu...

Research Advances Understanding of Amniotic Tissue as Potential Unique Treatment for Painful Chronic Condition that Affects 242 Million People Globally MARIETTA, Ga., Sept. 21, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Compan...

On a preliminary basis, MiMedx Group (MDXG) expects Q3 sales of $61M - 64M, down 28 - 31% from a year ago although the Q3 2019 sales included a $21.5M benefit from a change in its methods of revenue recognition from the time of cash collection to the time of shipment.Beginning today, certain ...

MiMedx (MDXG) expects Q3 net sales of $61M-$64M down from $88.9M in 3Q19. 3Q19 $88.9M sales include a benefit of $21.5M resulting from a change in the Company’s methods for recognizing revenue.The company will hold conference calls with institutional investors beginning September 21, 2...

Third Quarter 2020 Net Sales Expected to be Between $61 Million - $64 Million Latest Corporate Presentation Filed with SEC and Posted to IR Website 2020 Annual Meeting of Shareholders to be Held on November 20, 2020 MARIETTA, Ga., Sept. 21, 2020 (GLOBE ...

MiMedx ( OTCPK:MDXG -0.1% ) has completed enrollment in its Phase 3 study of micronized dehydrated Human Amnion Chorion Membrane (dHACM) injection, for plantar fasciitis, an inflammation of the fibrous tissue along the bottom of the foot that results in intense pain. Mor...

Research in Plantar Fasciitis Advances Understanding of Amniotic Tissue as Potential Treatment for Chronic Musculoskeletal Pain and Function Disorders MARIETTA, Ga., Sept. 17, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company&#x...